Grant Finder

LLS investigators are outstanding scientists at the forefront of leukemia, lymphoma and myeloma research at centers throughout the world. Search to see the many research projects that LLS is currently funding.

Grant: 1345-18 | Career Development Program (CDP):

Location:The University of Utah, Salt Lake City, Utah 84112-9003

Year: 2017

Project Title: MicroRNAs In Myeloid Leukemia Development And Resistance To Chemotherapy

Project Summary:

Mutations in genes that control cell growth and survival are commonly found in leukemia. In the case of acute myeloid leukemia (AML) there is often a mutation in a gene called FLT3 that causes it to be activated all the time and promote disease. However, there are many aspects of how this mutated gene is able to promote AML that remain unclear, making it challenging to design and develop new therapies against this devastating condition. My lab studies a newly discovered class of molecules, called microRNAs, which are altered in diseases such as leukemia.

Grant: 5468-18 | Career Development Program (CDP):

Location:New York University School of Medicine, Boston, Massachusetts 02241-415026

Year: 2017

Project Title: Understanding The Function Of 3D Chromatin Topology In Myeloid Disease

Project Summary:

Greater understanding of the fundamental mechanisms promoting the development of acute myeloid leukemia (AML) may help researchers develop new treatment approaches targeting these mechanisms. Chromosomes (collections of DNA and their associated proteins) are heritable and dynamic carriers of genetic information. Chromosomes are constantly looping, and these structural changes shape the gene expression pattern of a cell. This 3D genome landscape, known as genome topology, provides the physical structure required to inform the identity and function of a cell.

Grant: 1351-18 | Career Development Program (CDP):

Location:The Ohio State University, Columbus, Ohio 43210

Year: 2017

Project Title: Understanding And Overcoming Resistance To Bruton Tyrosine Kinase Inhibitors In Chronic Lymphocytic Leukemia

Project Summary:

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and until recently was treated with therapies toxic to the patient. Our clinical and research team at The Ohio State University Comprehensive Cancer Center helped provide critical information which led to the FDA approval of ibrutinib, a less toxic targeted therapy. Ibrutinib inhibits the BTK protein, which is a protein that CLL uses for its own pathological survival. Ibrutinib shows remarkable clinical activity that is more durable than any therapy ever studied in CLL.

Grant: 3374-18 | Career Development Program (CDP):

Location:Brigham and Women’s Hospital, Boston, Massachusetts 02241-3149

Year: 2017

Project Title: Functional Characterization Of The Mutant Calreticulin-MPL Interaction In Myeloproliferative Neoplasms

Project Summary:

Myeloproliferative neoplasms (MPN) are a group of rare blood cancers that occur when the body produces too many white blood cells, red blood bloods, or platelets. Though the overall prognosis for MPN tends to be favorable, more advanced forms of these diseases can lead to severe anemia, increased risk of blood clots, and transformation to leukemia. MPN were first described in 1951 by hematologist William Dameshek, but the underlying genetic cause of these diseases remained a mystery for over 50 years.

Grant: 1346-18 | Career Development Program (CDP):

Location:University of Cincinnati, Cincinnati, Ohio 45221-0222

Year: 2017

Project Title: The Oncogenic Role And Underlying Mechanism Of TET1 In Acute Myeloid Leukemia

Project Summary:

Acute myeloid leukemia (AML) is one of the most common and fatal forms of hematopoietic malignancies. Thus, it is urgent to better understand the mechanisms underlying the pathogenesis of AML, and on the basis of such understanding, to develop novel therapies with higher efficacy and minimal side effects to treat AML. The properties of cancer are often determined by the proteins that are expressed from information provided by the genes in the cell.

Grant: 5462-18 | Career Development Program (CDP):

Location:Yale University, New Haven, Connecticut 06520-8327

Year: 2017

Project Title: A Protein Degradation Approach For The Treatment Of Acute Myeloid Leukemia

Project Summary:

Many cancers result from a genetic mutation causing an “always on” protein. Current treatments are based on the deactivation of the proteins by blocking that protein’s active site. Herein I propose an alternative approach in which proteins are permanently degraded rather than temporarily deactivated, which may prove to be a more favourable form of therapy. To do this, I will take advantage of the cell’s own natural ability to degrade its own proteins when they are in excess or no longer needed.

Grant: 1344-18 | Career Development Program (CDP):

Location:Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024

Year: 2017

Project Title: The Biological And Therapeutic Consequences Of SF3B1 Mutations In Myelodysplastic Syndromes

Project Summary:

Myelodysplastic syndromes (MDS) are a group of blood disorders characterized by impaired differentiation of hematopoietic stem cells into functional blood cells. MDS frequently has a poor prognosis and is associated with a high risk of transformation into acute myeloid leukemia. There are few treatment options for MDS, largely because the underlying molecular changes that drove MDS were not known until recently. 

Grant: 5465-18 | Career Development Program (CDP):

Location:The Regents of the University of California, San Francisco, San Francisco, California 94143

Year: 2017

Project Title: Inhibiting The Palmitoylation/Depalmitoylation Cycle As A Selective Therapeutic Strategy In NRAS Mutant Leukemia.

Project Summary:

Acute myeloid leukemia (AML) is an aggressive blood cancer that affects children and adults. Recent advances for sequencing the DNA of leukemia cells have greatly advanced our understanding of the genetic causes of AML; however, this new knowledge has not yet resulted in better treatments. 

Grant: R0858-18 | Quest for CURES (QFC):

Location:University of Miami, Atlanta, Georgia 30384-5803

Year: 2017

Project Title: The Aging Epigenome: Clues To The Pathogenesis Of MDS

Project Summary:

Myelodysplastic syndromes (MDS) are diseases of the blood-producing cells in the bone marrow (BM) with a high risk for progression to an aggressive acute leukemia. While rare before the age of 50, its incidence increases significantly with every decade of age and thus it is likely that age-acquired changes in the BM may predispose to the development of MDS. However, the mechanism behind this increased incidence is not fully understood. We propose that as we age, cells in the bone marrow accumulate changes in the nuclear instructions that govern their behavior.

Grant: 3372-18 | Career Development Program (CDP):

Location:The Trustees of Columbia University in the City of New York, Columbia University Medical Center, New York, New York 10027

Year: 2017

Project Title: The Role Of Diverse Cytokines Secreted By Myeloid-biased Multipotent Progenitors In Driving Leukemia

Project Summary:

Myelogenous leukemia is a type of blood cancer characterized by the abnormal production of white blood cells in the bone marrow. Abnormally produced white blood cells prevent the proper production of healthy blood cells and eventually lead to failure of the healthy blood system. There are several well-known disease-causing mutations, and many researchers are studying them to find out how the mutations cause disease and to develop treatments based on the targeting of those mutations.

Pages